Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China

18. oktober 2017 oppdatert av: Baxter Healthcare Corporation

A Multicenter, Randomized, Open-Label Study of Quality of Life in Peritoneal Dialysis and Conventional In-Center Hemodialysis (ChinaQ Study)

This is a multicenter, randomized, open-label study to compare QoL in subjects with end-stage renal disease (ESRD) requiring PD or conventional in-center HD treatment.

Primary Objective: The primary objective is to demonstrate non-inferiority of peritoneal dialysis (PD) treatment as compared to hemodialysis (HD) treatment after approximately 1 year of therapy using the Kidney Disease Quality of Life-Short Form (KDQoL-SF) questionnaire domain of burden of kidney disease.

Secondary Objectives: The secondary objectives are to observe and summarize the following parameters in subjects receiving PD or HD treatment except for the remaining domains of QoL instrument KDQoL-SF™ (version 1.3) and the 2 individual QoL items scored as single items, which will be compared between the 2 treatment groups:

  • Mortality rates
  • Switch (PD to HD or HD to PD)
  • Transplantation rate
  • Cause of death
  • Dialysis adequacy (ie, urea clearance time normalized by total body water, which is the volume of distribution of urea [Kt/V urea] to determine the proportion of subjects meeting standards of care for dialysis adequacy).
  • 24-hour urine volume
  • Change in hemoglobin and S-phosphate levels, and the percentages of subjects with values within the target range
  • Change in serum albumin
  • Frequency of adverse events (AEs) and serious AEs (SAEs), including abnormal laboratory test findings with clinical significance

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

668

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Fujian
      • Fuzhou, Fujian, Kina
        • The First Affiliated Hospital of Fujian Medical University
    • Gansu
      • Lanzhou, Gansu, Kina
        • Lanzhou University Second Hospital
    • Guangdong
      • Guangzhou, Guangdong, Kina
        • The Third Hospital of Sun Yat-Sen University
      • Guangzhou, Guangdong, Kina, 510080
        • The First Affiliated Hospital , Sun Yet-Sen University
      • Guangzhou City, Guangdong, Kina
        • Guangzhou Panyu Central Hospital
      • Shenzhen, Guangdong, Kina
        • The 2nd Shenzhen Municipal People's Hospital
    • Guizhou
      • Gui Yang City, Guizhou, Kina
        • GuiZhou Province People's Hospital
    • Heilongjiang
      • Harbin City, Heilongjiang, Kina
        • The Second Affiliated Hospital of Harbin Medical University
    • Hubei
      • Wuhan City, Hubei, Kina
        • Traditional Chinese Medicine Hospital of Wuhan
    • Hunan
      • Changsha, Hunan, Kina
        • The Third Xiangya Hospital of Central South University
    • Jiangsu
      • Suzhou, Jiangsu, Kina
        • The Second Affiliated Hospital of Soochow University
    • Jiangxi
      • Nanchang, Jiangxi, Kina
        • Jiangxi province people's hospital
      • Nangchang, Jiangxi, Kina
        • Nanchang First Affiliated Hospital
    • Liaoning
      • Dalian, Liaoning, Kina
        • First Hospital of Affiliated of Dalian Medical University
    • Ningxia
      • Yingchuan, Ningxia, Kina
        • General Hospital of Ningxia Medical University
    • Shanghai
      • Shanghai, Shanghai, Kina
        • Shanghai Xinhua hospital
      • Shanghai, Shanghai, Kina
        • Shanghai Tenth People's Hospital
      • Shanghai, Shanghai, Kina, 200127
        • Renji Hospital , Shanghai Jiaotong University , School of Medicine
      • Shanghai, Shanghai, Kina
        • Shanghai 455 Hospital
    • Sichuan
      • Chengdu, Sichuan, Kina
        • Sichuan Provincial People's Hospital
    • Tianjin
      • Tianjin, Tianjin, Kina
        • The First Affiliated Hospital of Tianjin University of TCM

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Subjects or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF)
  2. Male or female subjects aged 18 years or older at the time of randomization
  3. Subjects diagnosed with ESRD (ie, an estimated glomerular filtration rate ≤15 mL/min/1.73 m2 body surface area) and who the Investigator anticipates will require maintenance dialysis therapy within 10 weeks after signing the ICF
  4. Subjects who, as judged by the Investigator, are able to comprehend the standardized, predialysis education program and have completed this education prior to signing the ICF
  5. Subjects or their legal representative who, as judged by the Investigator, are capable of being trained for home-based PD
  6. Subjects who are able to adhere to the study visit schedule and other protocol requirements
  7. Subjects who are able to come to HD clinics as required by the protocol
  8. Subjects who, as judged by the Investigator, are expected to remain on dialysis for at least 48 weeks
  9. Subjects who have normal liver function, as judged by the Investigator
  10. Female subjects of childbearing potential must have negative serum or urine pregnancy test at Screening. Sexually active women of childbearing potential must agree to use adequate contraceptive methods, as judged by the Investigator, while in the study

Exclusion Criteria:

  1. Subjects who are HIV positive
  2. Subjects who have already received maintenance dialysis. Subjects are not excluded if a functional dialysis access is present ≤4 weeks before Screening for back-up purposes or for acute treatment of life-threatening uremic symptoms, electrolyte abnormalities or fluid overload
  3. Subjects who have an active infection or other condition that the Investigator determines may jeopardize their ability to receive either modality of dialysis treatment or would preclude participation in the study
  4. Subjects who report a history of illicit drug use or a regular or daily alcohol consumption of ≥4 alcoholic drinks per day in the 2 years before Screening
  5. Subjects who have previously received renal transplantation and are currently prescribed immunosuppressive therapy
  6. Subjects who are currently using any investigational drug
  7. Subjects who are currently enrolled in other clinical studies
  8. Subjects who are unwilling or unable to fully comply with the visits and assessments required by the protocol
  9. Subjects who are not eligible for either PD or HD, as judged by the Investigator, due to:

    • Peritoneal dialysis: documented extensive intra-peritoneal adhesions or other conditions in which PD is contraindicated
    • Hemodialysis: severe cardiac instability or other conditions in which HD is contraindicated
  10. Subjects who have a malignancy requiring chemotherapy or radiation therapy
  11. Subjects undergoing temporary dialysis treatment between the Screening visit and Day 1 visit that is expected to exceed 6 weeks in duration
  12. Subjects who have a life expectancy of < 48 weeks

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: ESRD patients receiving HD treatment
no investigational drug involved. Only observe therapy treatment
Eksperimentell: ESRD patients receiving PD treatment
no investigational drug involved. Only observe therapy treatment

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
1 year of therapy using the Kidney Disease Quality of Life-Short Form (KDQoL-SF) questionnaire
Tidsramme: 1 year
1 year

Sekundære resultatmål

Resultatmål
Tidsramme
Mortality rates
Tidsramme: 1 year
1 year
Switch (PD to HD or HD to PD)
Tidsramme: 1 year
1 year
Transplantation rate
Tidsramme: 1 year
1 year
Cause of death
Tidsramme: 1 year
1 year
Dialysis adequacy
Tidsramme: 1 year
1 year
24-hour urine volume
Tidsramme: 1 year
1 year
Change in hemoglobin
Tidsramme: 1 year
1 year
Change in serum albumin
Tidsramme: 1 year
1 year
Frequency of adverse events (AEs) and serious AEs (SAEs), including abnormal laboratory test findings with clinical significance
Tidsramme: 1 year
1 year
Change in S-phosphate levels
Tidsramme: 1 year
1 year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

26. mars 2014

Primær fullføring (Faktiske)

18. september 2017

Studiet fullført (Faktiske)

18. september 2017

Datoer for studieregistrering

Først innsendt

10. februar 2015

Først innsendt som oppfylte QC-kriteriene

26. februar 2015

Først lagt ut (Anslag)

4. mars 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

20. oktober 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. oktober 2017

Sist bekreftet

1. oktober 2017

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 8339-001

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

3
Abonnere